Wire · opportunities
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA approved Weltruza, the first once-monthly subcutaneous long-acting injectable formulation of olanzapine for treating schizophrenia in adults, after successful phase 3 trial results demonstrating efficacy and no need for oral supplementation or post-injection monitoring.
This Wire brief sits within Fusion42's coverage of Health, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
Your access to schizophrenia treatment just shifted with FDA approval of a monthly injection removing daily doses. You can now offer patients and care teams relief from adherence challenges without extra monitoring.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics